middle.news
Prescient Therapeutics Advances PTX-100 Trial with FDA Nod and New CEO
6:05pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Prescient Therapeutics Advances PTX-100 Trial with FDA Nod and New CEO
6:05pm on Sunday 1st of June, 2025 AEST
Key Points
FDA clears IND application for PTX-100 Phase 2 trial in r/rCTCL
Progress in CellPryme and OmniCAR cell therapy platforms with growing collaboration interest
Cash reserves of $8.4 million at December 2024, plus $3.7 million R&D tax rebate received in January
New CEO James McDonnell appointed, bringing extensive biopharma leadership experience
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE